FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to therapy, and can be used in the treatment of mild and moderate coronavirus infection (MCVI). Method includes etiotropic and interferon therapy, additionally Rexod is administered intravenously in the amount of 9.6 million IU once a day for 5 days.
EFFECT: use of the invention makes it possible to prevent the development of complications of MCVI by reducing the activity of the systemic inflammatory response and preventing the development of a "cytokine storm", as well as to reduce the duration of the disease and the duration of temporary disability.
3 cl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
| METHOD FOR TREATING PATIENTS WITH HIV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASES WITH MODERATE AND SEVERE COVID-19 | 2022 |
|
RU2793414C1 |
| METHOD OF REHABILITATION, COMBINING HYPO- AND HYPERBARIC OXYGENATION, FOR PATIENTS SUFFERING NEW CORONAVIRUS INFECTION | 2023 |
|
RU2821549C1 |
| METHOD FOR THE TREATMENT OF THROMBOCYTOPENIA IN CORONAVIRUS INFECTION | 2022 |
|
RU2783888C1 |
| METHOD OF PREDICTING THE RISK OF DEVELOPING CHRONIC HEART FAILURE IN PATIENTS WHO HAVE HAD A NEW CORONAVIRUS INFECTION COVID-19 | 2023 |
|
RU2805601C1 |
| TECHNOLOGY OF REHABILITATION-PREVENTIVE NUTRITIONAL SUPPORT IN CORONAVIRUS INFECTION | 2020 |
|
RU2735723C1 |
| APPLICATION OF METHOD FOR ADMINISTRATION OF SODIUM SALT OF 2-METHYLTHIO-6-NITRO-1,2-4-TRIAZOL[5,1-C] -1,2,4-TRIAZIN-7-ONE, DIHYDRATE WITH ANTIVIRAL ACTIVITY, FOR TREATMENT OF CORONAVIRUS INFECTION COVID-19 | 2021 |
|
RU2754532C1 |
| PREPARATION FOR COMPLEX THERAPY OF DISEASES CAUSED BY BETA-CORONAVIRUSES | 2020 |
|
RU2739212C1 |
| METHOD FOR PREDICTING THE LETHAL OUTCOME IN PATIENTS WITH SEVERE CoVID-19 | 2021 |
|
RU2780748C1 |
| METHOD FOR TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH SARS-CoV-2 | 2021 |
|
RU2780939C1 |
